Stabilized 9 and 10 segmented influenza viruses as a vaccine platform and methods of making and using same
AssigneeDuke University
InventorsNicholas S. Heaton, Alfred Harding, Griffin Haas, Alanson Girton
Life of this patent
Estimating the term…
Abstract
The present invention provides a modified influenza A virus (IAV) comprising, consisting of, or consisting essentially of at least one artificial gene segment comprising a duplicated packaging signal, the result of which is a modified IAV that is replication competent and avirulent, and when co-infected with a wild type virus leads to segment exchange and compromises the spread of both viruses as well as methods of making and using same and methods of using the IAVs in the treatment and prevention of influenza-related diseases.
Claims20
A polynucleotide construct or set of constructs comprising:
- (i) a first domain comprising from 5′ to 3′:
- a 5′ packaging signal of polymerase acid (PA), a polynucleotide sequence encoding polymerase basic subunit 2 (PB2), and a 3′ packaging signal of PA;
- (ii) a second domain comprising from 5′ to 3′:
- a 5′ packaging signal of PB2, a first heterologous polynucleotide sequence, and a 3′ packaging signal of PB2;
- and
- (iii) a third domain comprising from 5′ to 3′:
- the 5′ packaging signal of PA, a polynucleotide sequence encoding PA, and the 3′ packaging signal of PA;
- wherein the construct or set of constructs can be used to produce a replication competent modified influenza A virus (IAV) having at least nine gene segments.
Dependencies are inferred from the claim text.